Clinical efficacy and prognosis analysis of ifosfamide and cisplatin in the treatment of recurrent retroperitoneal sarcoma
10.13699/j.cnki.1001-6821.2015.20.009
- VernacularTitle:异环磷酰胺联合顺铂治疗复发性腹膜后肉瘤的临床疗效及预后分析
- Author:
Xin-Jun ZHOU
1
;
Lin-Guo YAO
;
Xi-Ping DING
;
Ji-Zhou SHI
;
Xing LEI
Author Information
1. 胜利油田中心医院 胃肠外科
- Keywords:
ifosfamide;
recurrent retroperitoneal sarcoma;
cisplatin prognosis
- From:
The Chinese Journal of Clinical Pharmacology
2015;(20):2011-2013
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and prognosis analysis of ifosfamide and cisplatin in the treatment of recurrent retro-peritoneal sarcoma.Methods A total of 55 cases of recurrent retro-peritoneal sarcoma patients were divided into treatment group(28 cases) and control group ( 27 cases ) .Patients in treatment group were treated with cisplatin 20-30 mg? m -2 intravenous infusion, continuous to use 3 to 5 days for a course of treatment, repeated administration three weeks later, treatment for 3 to 4 courses;ifosfamide 1.2-2.0 g? m-2 daily, 5 days a course, 3 to 4 weeks a repeat, 4 courses treatment.Patients in control group were treated with ifosfamide only.Clinical efficacy of the two groups were observed, living conditions and adverse reactions were observed after 6,12,24 months treatment.Results Total effective rate in treatment group was 64.25%, significantly higher than that (29.63%)in control group (P <0.05).Survival rates of 6, 12, 24 months in treatment group were 92.86%, 85.71%, 67.87%, and control group were 92.59%, 81.48%and 55.56%, with no significant difference (P>0.05).The incidence of adverse reactions in treatment group was 60.71%, with no significant difference with control group, which was 59.26%(P>0.05).Conclusion The effect of ifosfamide combined with cisplatin in the treatment of re-current retroperitoneal sarcoma was relatively better, and the combination can improve the survival rate and quality of life, worth recommended to clinical use.
